Live or Let Die: T Cell Survival in Cancer Immunotherapy
- PMID: 30784574
- DOI: 10.1016/j.immuni.2019.01.016
Live or Let Die: T Cell Survival in Cancer Immunotherapy
Abstract
Combination immune checkpoint blockade targeting CTLA-4 and PD-1 is thought to reinvigorate exhausted T cells better than monotherapies. In this issue of Immunity, Pai et al. (2019) show that, in the setting of low tumor burden, this combination regimen promotes interferon-γ-dependent T cell hyperactivation and death and thus favors tumor progression.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006. Epub 2019 Feb 5. Immunity. 2019. PMID: 30737146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources